MAGENTIQ EYE Secures Series A for AI-Powered Gastroenterology Future
MAGENTIQ EYE Secures Series A Investment to Revolutionize AI-Powered Gastroenterology
Haifa, Israel – August 4, 2025 – MAGENTIQ EYE LTD., a pioneering force in artificial intelligence (AI)-powered decision-support software for gastroenterology, has successfully closed its Series A funding round. The investment was spearheaded by aMoon, Israel's largest HealthTech investment fund, with significant participation from a consortium of international investors including Norgine Ventures BV (Netherlands), Nina Capital (EU & USA), Namarel Ventures SL (Spain), Nova Capital (Italy), and private investors Sake Bosch and Roon Doornink (USA). This crucial funding is set to accelerate MAGENTIQ EYE's innovation, market expansion, and global reach in the rapidly evolving field of AI in healthcare.
MAGENTIQ EYE's flagship product, MAGENTIQ-COLO™, is an FDA- and CE-approved software designed to significantly enhance polyp detection and analysis during colonoscopies. The software provides real-time insights, improving adenoma detection rates, which is critical given that even a one percent increase in adenoma detection can lead to a three percent decrease in colorectal cancer occurrence. The CE-approved version of MAGENTIQ-COLO™ further offers advanced features such as polyp-size categorization, type estimation, and AI-generated reports. The system seamlessly integrates into existing clinical workflows, acquiring digital video signals from endoscopy towers and highlighting suspicious areas with bounding boxes on the main screen or a separate monitor, thereby drawing the gastroenterologist's attention.
The proceeds from this Series A round will primarily fuel the continued development and expansion of MAGENTIQ EYE's diagnostic tools. This includes ongoing clinical trials for diagnostic tools targeting specialized diseases in both the lower and upper gastrointestinal tracts, such as ulcerative colitis, early dysplasia in Barrett's esophagus, and gastric intestinal metaplasia. Additionally, the company is developing automated quality indicators for GI procedures. A significant portion of the investment will also drive commercial growth in the USA, Europe, and other global markets through a combination of direct sales and strategic partnerships with industry leaders.
Dror Zur, Ph.D., founder and CEO of MAGENTIQ EYE, expressed enthusiasm for the investment, stating that aMoon's support will accelerate innovation and market access, meeting the growing demand reflected in their robust pipeline of trial and purchase requests across the U.S. and Europe. Roy Wiesner, a partner at aMoon, will join MAGENTIQ EYE's board of directors, bringing valuable strategic insights and extensive experience in health tech. Wiesner lauded MAGENTIQ's solution as the most accurate on the market, citing its broad feature set, cost-effective scalability, and platform flexibility across GI and laparoscopic applications.
The investment underscores the burgeoning market for AI in endoscopy. The global AI in endoscopy market, valued at USD 58.1 million in 2023, is projected to reach approximately USD 838.9 million by 2033, demonstrating a compound annual growth rate (CAGR) of 30.6% during the forecast period. Another report estimates the market at USD 2.2 billion in 2024, with a projected growth to USD 21.1 billion by 2034 at a CAGR of 25.3%. This growth is driven by the increasing prevalence of gastrointestinal disorders, the escalating demand for minimally invasive diagnostic procedures, and the proven ability of AI to enhance diagnostic accuracy and operational efficiency. AI-powered innovations in this sector, including enhanced lesion detection, predictive analytics, and guided biopsies, are revolutionizing gastroenterology and improving patient outcomes.
aMoon, a global HealthTech and Life Sciences investment fund with over $1.3 billion in assets under management (AUM), is a prominent investor in companies leveraging groundbreaking science and technology to transform healthcare. As Israel's largest HealthTech fund, aMoon actively partners with entrepreneurs from early-stage ventures through growth and pre-IPO rounds, providing not only capital but also strategic guidance and access to a global network of experts. Their investment in MAGENTIQ EYE reflects their commitment to backing transformative health tech solutions that can dramatically improve patient outcomes worldwide.